Personalized medicine in sarcoidosis: predict responders and nonresponders
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33154233" target="_blank" >RIV/61989592:15110/15:33154233 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1097/MCP.0000000000000194" target="_blank" >http://dx.doi.org/10.1097/MCP.0000000000000194</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MCP.0000000000000194" target="_blank" >10.1097/MCP.0000000000000194</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Personalized medicine in sarcoidosis: predict responders and nonresponders
Popis výsledku v původním jazyce
PURPOSE OF REVIEW: Treatment of sarcoidosis, a granulomatous disease affecting multiple organs with predominance to the lung, is complicated by variable response of individual patients to treatment options ranging from corticosteroids to second-line steroid-sparing agents and further to biologicals. This is partially because of varying disease manifestation, but polymorphic genes affecting drug metabolization substantially contribute. This review deals with pharmacogenetic (PGx) factors underlying interindividual differences of treatment response in sarcoidosis regarding personalized approach to patient management. RECENT FINDINGS: No firm evidence is available for introducing genotyping metabolizing enzymes and/or transporters (Cytochrome P450, TPMT,ABCB1 and so on) despite drugs they target (azathioprine and methotrexate) are used in sarcoidosis. Variation in TNFA gene, which was associated with response to tumor necrosis factor inhibitors (infliximab and adalimumab), is in line wit
Název v anglickém jazyce
Personalized medicine in sarcoidosis: predict responders and nonresponders
Popis výsledku anglicky
PURPOSE OF REVIEW: Treatment of sarcoidosis, a granulomatous disease affecting multiple organs with predominance to the lung, is complicated by variable response of individual patients to treatment options ranging from corticosteroids to second-line steroid-sparing agents and further to biologicals. This is partially because of varying disease manifestation, but polymorphic genes affecting drug metabolization substantially contribute. This review deals with pharmacogenetic (PGx) factors underlying interindividual differences of treatment response in sarcoidosis regarding personalized approach to patient management. RECENT FINDINGS: No firm evidence is available for introducing genotyping metabolizing enzymes and/or transporters (Cytochrome P450, TPMT,ABCB1 and so on) despite drugs they target (azathioprine and methotrexate) are used in sarcoidosis. Variation in TNFA gene, which was associated with response to tumor necrosis factor inhibitors (infliximab and adalimumab), is in line wit
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FC - Pneumologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Current Opinion in Pulmonary Medicine
ISSN
1070-5287
e-ISSN
—
Svazek periodika
21
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
6
Strana od-do
532-537
Kód UT WoS článku
000364415300015
EID výsledku v databázi Scopus
—